IDENTIFY: The Investigation and DEtection of urological Neoplasia in paTIents reFerred with suspected urinarY tract cancer: A multicentre analysis
BAUS ePoster online library. Khadhouri S. 06/24/19; 259504; P2-1
Mr. Sinan Khadhouri
Mr. Sinan Khadhouri
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)

To determine contemporary urinary tract cancer rates and diagnostic test performance in patients referred to secondary care with suspected urothelial cancer.

Materials & Methods

IDENTIFY is the largest ever prospective, international study of patients referred to secondary care with haematuria. Extensive data on patient demographics, presenting features and diagnostic test results were recorded.


11,130 patient records were collected from 111 hospitals in 28 countries (Dec 2017 - Dec 2018). The prevalence of bladder cancer [BC] overall was 14.2%; 18.1% in VH, 3.7% in NVH. Upper tract urothelial cancer [UTUC] prevalence was 1% overall, renal cell carcinoma [RCC] 0.9% and prostate cancer 1.2%.

Variables significantly associated with BC included type of haematuria, age, smoking history, anticoagulation, storage urinary tract symptoms and having had >1 episode of VH (25.5%) vs. only 1 (17.9%). UTUC was significantly associated with type of haematuria, age, smoking and anticoagulation. The rate of BC found in those with culture proven urinary tract infection [UTIs] was 7.0%, which was significantly lower than in those without UTI (19.7%). The diagnostic performance of ultrasound [US] and Computed Tomography [CT] is given in Table 1.


IDENTIFY provides contemporary cancer detection rates in a global population alongside extensive predictive data and diagnostic test performance for each cancer type. The detailed data will allow complex interactions between predictive variables to be appreciated and develop a personalised approach to haematuria investigations. This should improve shared decision-making and optimise cancer detection whilst minimising investigative burden.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings